Leaflet ZENAPAX 5mg / ml concentrate for solution for infusion
Indicated for: multiple sclerosis
Route of administration: infusion
Substance: daclizumab (monoclonal antibody)
ATC: L04AA08 (Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Daclizumab is an immunomodulatory medication previously used for the treatment of relapsing multiple sclerosis. It worked by blocking the interleukin-2 (IL-2) receptor, reducing immune system activity that attacks the myelin in the central nervous system.
The medication was administered as subcutaneous injections, usually once a month. While effective in reducing relapse frequency, its use was associated with significant risks.
Side effects included infections, injection site reactions, fatigue, and, in rare cases, severe liver conditions or autoimmune disorders. Due to these risks, Daclizumab was withdrawn from the market in many countries.
Consult your doctor for safe and effective alternatives for managing multiple sclerosis. Close monitoring is essential to manage this condition effectively.
General data about ZENAPAX 5mg / ml
- Substance: daclizumab
- Date of latest medicines list: 01-07-2013
- Product code: W07557002
- Concentration: 5mg / ml
- Pharmaceutical form: concentrate for solution for infusion
- Quantity: 3
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.